Treatment of cocaine cardiovascular toxicity: a systematic review

  title={Treatment of cocaine cardiovascular toxicity: a systematic review},
  author={John R. Richards and D Garber and Erik G. Laurin and Timothy E. Albertson and Robert W. Derlet and Ezra A. Amsterdam and Kent R. Olson and Edward A. Ramoska and Richard A. Lange},
  journal={Clinical Toxicology},
  pages={345 - 364}
Abstract Introduction: Cocaine abuse is a major worldwide health problem. Patients with acute cocaine toxicity presenting to the emergency department may require urgent treatment for tachycardia, dysrhythmia, hypertension, and coronary vasospasm, leading to pathological sequelae such as acute coronary syndrome, stroke, and death. Objective: The objective of this study is to review the current evidence for pharmacological treatment of cardiovascular toxicity resulting from cocaine abuse. Methods… 

β-blocker treatment of vascular disease in cocaine addiction.

In-Hospital and Long-Term Outcomes of Beta-Blocker Treatment in Cocaine Users: A Systematic Review and Meta-analysis

The results suggest that β-blocker treatment in patients presenting with cocaine intoxication may not be as harmful as originally believed.

β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon

The pathophysiology, pharmacology, and published evidence behind the unopposed α-stimulation phenomenon are investigated, including the unique and deleterious pharmacologic properties of cocaine in the absence of β-blockers.

Dual cocaine and methamphetamine cardiovascular toxicity: rapid resolution with labetalol.

Stimulant and Designer Drug Use: Primary Care Management.

The clinical effects and treatment of persons who use cocaine, methamphetamines, 3,4-methylenedioxymethamphetamine (MDMA), synthetic cannabinoids, and synthetic cathinones are reviewed.

Metoprolol treatment of dual cocaine and bupropion cardiovascular and central nervous system toxicity

Clinicians should be aware of the potential for synergistic cardiovascular and CNS toxicity from concomitant cocaine and bupropion use and metoprolol, a lipophilic beta-blocker, has good penetration of the CNS and can counter stimulant-induced agitation.

Cerebrovascular and cardiovascular diseases caused by drugs of abuse

Differential diagnosis is essential because of the likelihood of life-threatening events, especially among young people who exhibit cerebrovascular and cardiovascular diseases without any of the typical risk factors, and careful differential diagnosis and selection of therapeutic agents is required.



Should β-Blockers Be Used in the Treatment of Cocaine-Associated Acute Coronary Syndrome?

Objective: To critically evaluate the 30 year debate of β-blocker use in cocaine-induced acute coronary syndrome (CIACS). Data Sources: An Ovid MEDLINE In-Process and Other Non-Indexed Citations,

Should beta-blockers be used in the treatment of cocaine-associated acute coronary syndrome?

Beta-blockers should not be considered first-line agents for controlling chest pain in patients with documented CIACS, and its benefits should be weighed against recurrent use of cocaine and possible exacerbation of acute coronary syndrome.

Rethinking cocaine-associated chest pain and acute coronary syndromes.

In this review, the limited historical evidence underlying the current teachings on cocaine's cardiovascular effects and management of cocaine-associated chest pain is critically evaluated and an algorithm is reviewed based on the current best evidence.

Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology.

The goals of the present article are to provide a critical review of the literature on cocaine-associated chest pain and myocardial infarction (MI) and to give guidance for diagnostic and therapeutic

Beta-blockers for chest pain associated with recent cocaine use.

Beta-Blockers do not appear to be associated with adverse events in patients with chest pain with recent cocaine use, and patients discharged on a beta-blocker regimen exhibited a significant reduction in cardiovascular death.

Nitroglycerin in the treatment of cocaine associated chest pain--clinical safety and efficacy.

A prospective multicenter observational study to evaluate the clinical safety and efficacy of nitroglycerin in the treatment of cocaine associated chest pain found that the treated patients were at higher risk of ischemic heart disease.

Cocaine-related medical problems: consecutive series of 233 patients.

Death temporally related to the use of a beta adrenergic receptor antagonist in cocaine associated myocardial infarction

A 54-year-old man brought to the emergency department complaining of chest pain after using approximately 1 gram of intranasal cocaine was supported by the potential lethality of a cocaine-beta adrenergic receptor antagonist interaction.

Cocaine-induced myocardial infarction in patients with normal coronary arteries.

Experimental evidence suggests that cocaine has direct and indirect sympathomimetic effects on vascular smooth muscle, attenuates endothelium vasodilator capacity, exerts a potent depressant effect on cardiac myocytes, and promotes atherogenesis after chronic cocaine use.